Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.
about
Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationLX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotoninComparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C.Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors.Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.Efficacy of ramosetron in male patients with irritable bowel syndrome with diarrhea (neurogastroenterol motil 2011;23:1098-1104).A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event LogEffects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.Systematic review: symptom assessment using patient-reported outcomes in gastroesophageal reflux disease and dyspepsia.Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population.Study design considerations for irritable bowel syndrome clinical trials.Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria.Validation of a bowel function diary for assessing opioid-induced constipation.Gastrointestinal well-being in subjects reporting mild gastrointestinal discomfort: characteristics and properties of a global assessment measure.Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
P2860
Q30433548-D414E828-ADAF-4A29-85DE-03B17E4332B8Q33695487-6A493328-D7C9-491D-A0BB-192508350B39Q34790812-F74506DD-7FF5-4FC4-A55A-FF720AF2A631Q35044200-FAB65222-28F9-49E6-B929-E9AA0EBDEC10Q35435130-F3E9CF71-6B4E-44A9-B6F5-26CC3FD5DF37Q35586987-0A7D8B99-67A8-4BD4-AA66-3D9153BA9D7AQ35885931-659BFC5A-6748-477E-B396-A6EAB5A67948Q35939253-641D3FD3-6531-497D-A36F-462703001B5EQ36297736-D3A3ED03-ECCB-45C6-BF76-7D911FA431A8Q36310200-39C54CFA-89A0-4477-8D38-B5702A6FED63Q36487263-F56599C5-37C9-4B2D-8C67-6950E816B950Q37405205-E873589A-3A6C-45F3-8944-15780EC549BCQ37561248-CF010A24-6334-4248-B557-8F1C0F29F4DDQ38045930-8D67BFD2-6B80-4857-924A-1599F4B3EEC4Q38102063-9975D6DE-D9F4-422A-8EC1-C8C9470FB605Q41078368-851CCA5E-4C2E-49FC-9892-1D8680F2A18FQ42934168-B0C6DB34-D528-4DD9-8B09-C8C92EFA9E9CQ43327979-0B765CB2-B790-4489-BC5D-C14688E69B20Q44348353-94D8459C-EFD7-4504-9B5D-6E71E7AA9872Q48293657-091EDBA4-E2E9-4CD7-B89C-282778775D94Q51419778-AC7107E3-D3D6-4ACE-A66A-ABC25CA057AD
P2860
Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Evolution of clinical trials f ...... n end points and study design.
@en
Evolution of clinical trials f ...... n end points and study design.
@nl
type
label
Evolution of clinical trials f ...... n end points and study design.
@en
Evolution of clinical trials f ...... n end points and study design.
@nl
prefLabel
Evolution of clinical trials f ...... n end points and study design.
@en
Evolution of clinical trials f ...... n end points and study design.
@nl
P2093
P2860
P356
P1476
Evolution of clinical trials f ...... n end points and study design.
@en
P2093
Ann Marie Trentacosti
Dianne L Kennedy
Donna Griebel
Laurie B Burke
P2860
P304
P356
10.1038/AJG.2010.12
P407
P577
2010-04-01T00:00:00Z